	US 12,077,524 B2
	Crystal of pyrrolidine compound
Naoko Ueda, Osaka (JP); Hiroomi Nagata, Osaka (JP); and Takahiro Yoshida, Osaka (JP)
Assigned to MITSUBISHI TANABE PHARMA CORPORATION, Osaka (JP)
Appl. No. 17/418,563
Filed by MITSUBISHI TANABE PHARMA CORPORATION, Osaka (JP)
PCT Filed Dec. 27, 2019, PCT No. PCT/JP2019/051570 § 371(c)(1), (2) Date Jun. 25, 2021, PCT Pub. No. WO2020/138481, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. 2018-247437 (JP), filed on Dec. 28, 2018.
Prior Publication US 2022/0073497 A1, Mar. 10, 2022
Int. Cl. C07D 401/14 (2006.01)

CPC C07D 401/14 (2013.01) [C07B 2200/13 (2013.01)]

12 Claims

1. A crystal comprising an equimolar amount of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid and phosphoric acid, wherein the crystal is measured to show peaks at 5.7°, 11.5°, 13.9°, 19.0°, and 21.9° (±0.2° for each peak) as diffraction angles expressed in 2θ in a powder X-ray diffraction spectrum.